OTCMKTS:BICX - Biocorrx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.85 0.00 (0.00 %) (As of 03/21/2019 06:05 AM ET)Previous Close$3.85Today's Range$3.85 - $3.8552-Week Range$3.50 - $15.40Volume40 shsAverage Volume2,513 shsMarket Capitalization$10.01 millionP/E RatioN/ADividend YieldN/ABeta1.07 ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. The company distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. It is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is headquartered in Anaheim, California. Receive BICX News and Ratings via Email Sign-up to receive the latest news and ratings for BICX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BICX Previous Symbol CUSIPN/A CIK1443863 Webwww.biocorrx.com Phone714-462-4880Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$650,000.00 Price / Sales15.40 Cash FlowN/A Price / Cash FlowN/A Book Value($1.61) per share Price / Book-2.39Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-29,700,000.00 Net Margins-1,144.56% Return on EquityN/A Return on Assets-1,061.12%Miscellaneous EmployeesN/A Outstanding Shares2,600,000Market Cap$10.01 million Next Earnings DateN/A OptionableNot Optionable Biocorrx (OTCMKTS:BICX) Frequently Asked Questions What is Biocorrx's stock symbol? Biocorrx trades on the OTCMKTS under the ticker symbol "BICX." How were Biocorrx's earnings last quarter? Biocorrx Inc (OTCMKTS:BICX) announced its earnings results on Thursday, November, 17th. The company reported ($0.02) EPS for the quarter. The company earned $0.17 million during the quarter. View Biocorrx's Earnings History. Has Biocorrx been receiving favorable news coverage? Headlines about BICX stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biocorrx earned a news sentiment score of 3.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the next few days. Who are some of Biocorrx's key competitors? Some companies that are related to Biocorrx include Novus Therapeutics (NVUS), Helix Biopharma (HBPCF), Celsion (CLSN), AIT Therapeutics (AITB), DiaMedica Therapeutics (DMAC), Obalon Therapeutics (OBLN), ProPhase Labs (PRPH), Caladrius Biosciences (CLBS), Oncomed Pharmaceuticals (OMED), ImmuCell (ICCC), Valeritas (VLRX), TSO3 (TOS), Fuse Medical (FZMD), Amryt Pharma (AMYT) and Novoheart (NVH). What other stocks do shareholders of Biocorrx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocorrx investors own include MONDI/PAR VTG FPD 0.2 (MNDI), Cronos Group (CRON), Wells Fargo & Co (WFC), ImmunoGen (IMGN), Energen (EGN), SS&C Technologies (SSNC), Editas Medicine (EDIT), Nektar Therapeutics (NKTR), General Electric (GE) and Cisco Systems (CSCO). Who are Biocorrx's key executives? Biocorrx's management team includes the folowing people: Mr. Brady James Granier, Pres, CEO & Director (Age 47)Ms. Lourdes Felix, CFO, COO & Director (Age 51)Mr. Thomas Patrick Welch, VP of OperationsDr. George N. Fallieras, Medical Consultant How do I buy shares of Biocorrx? Shares of BICX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biocorrx's stock price today? One share of BICX stock can currently be purchased for approximately $3.85. How big of a company is Biocorrx? Biocorrx has a market capitalization of $10.01 million and generates $650,000.00 in revenue each year. What is Biocorrx's official website? The official website for Biocorrx is http://www.biocorrx.com. How can I contact Biocorrx? Biocorrx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The company can be reached via phone at 714-462-4880 or via email at [email protected] MarketBeat Community Rating for Biocorrx (OTCMKTS BICX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 54 (Vote Outperform)Underperform Votes: 49 (Vote Underperform)Total Votes: 103MarketBeat's community ratings are surveys of what our community members think about Biocorrx and other stocks. Vote "Outperform" if you believe BICX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BICX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: How is an ETF different from a mutual fund?